Grifols (GRFS) Change in Receivables (2010 - 2020)
Grifols' (GRFS) quarterly Change in Receivables came in at $1.5 million in Q1 2020, up 100.9% YoY from $738505.3 in Q2 2019, and up 109.81% on a QoQ basis from -$15.1 million in Q4 2019.
Grifols (GRFS) Change in Receivables (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Change in Receivables data on file, last reported at $1.5 million in Q1 2020.
- Quarterly Change in Receivables rose 100.9% year-over-year to $1.5 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$160.7 million (up 27.66% YoY) and the FY2025 annual result came in at -$37.2 million, up 17.0% from the prior year.
- Change in Receivables grew to $1.5 million in Q1 2020, from -$15.1 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $81.5 million in Q4 2017 to a low of -$163.9 million in Q1 2019.
- A 5-year average of -$4.0 million and a median of $3.5 million in 2016 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2017 — Change in Receivables soared 2206.94% — and 2019, when it plunged 1195.73%.
- Tracing GRFS's Change in Receivables over 5 years: stood at $3.5 million in 2016, then soared by 2206.94% to $81.5 million in 2017, then plunged by 79.25% to $16.9 million in 2018, then sank by 189.44% to -$15.1 million in 2019, then surged by 109.81% to $1.5 million in 2020.
- The last three Change in Receivables figures came in at $1.5 million (Q1 2020), -$15.1 million (Q4 2019), and -$163.9 million (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.18 Bn | 632.42 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 470.31 Bn | 463.74 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 377.76 Bn | 370.62 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.84 Bn | 252.94 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.85 Bn | 222.86 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 182.10 Bn | 178.92 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.40 Bn | 147.70 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.36 Bn | 102.19 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.44 Bn | 4.44 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 1.48 Mn |
| Mar 31, 2020 | 1.48 Mn |
| Dec 31, 2019 | -15.12 Mn |
| Dec 31, 2019 | -15.12 Mn |
| Mar 31, 2019 | -163.95 Mn |
| Mar 31, 2019 | -163.95 Mn |
| Dec 31, 2018 | 16.91 Mn |
| Dec 31, 2018 | 16.91 Mn |
| Jun 30, 2018 | -90.04 Mn |
| Jun 30, 2018 | -90.04 Mn |
| Mar 31, 2018 | 14.96 Mn |
| Mar 31, 2018 | 14.96 Mn |
| Dec 31, 2017 | 81.48 Mn |
| Dec 31, 2017 | 81.48 Mn |
| Jun 30, 2017 | -19.98 Mn |
| Jun 30, 2017 | -19.98 Mn |
| Mar 31, 2017 | 61.00 Mn |
| Mar 31, 2017 | 61.00 Mn |
| Dec 31, 2016 | 3.53 Mn |
| Dec 31, 2016 | 3.53 Mn |